RxDoctor Payments Data

Mark Henderson, MD

Radiation Oncology · Columbus, INNPI 1841370707

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 30 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by Sirtex Medical Inc at 25.0% of the total. Reporting peaked in 2019 at $411 and has fallen 71.3% since, to $118 in 2025.

$757in general payments, 2019–2025

Across 30 payments — averaging $25.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sirtex Medical Inc$189
  • Genentech USA, Inc.$114
  • AstraZeneca$47
  • Novartis$38
  • Eisai Inc.$34
  • Merck$27
  • plus $307 from 17 others

What the payments were for

  • Food & beverage$757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$757 in reported general payments places this provider in the 55th percentile of 116 radiation oncology providers in Indiana.

See all radiation oncology providers in Indiana

Medicare billing

Part B allowed, 2024
$231,487
Medicare patients
277
Services billed
2,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix13$35,538
Tamsulosin Hcl47$643
Pentoxifylline18$363
Mometasone Furoate24$358
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen22$349
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen21$212
Dexamethasone14$208
Bicalutamide16$187
Pantoprazole Sodium13$52

Paid to pharmacies, not to this prescriber.

Other radiation oncology in Columbus

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →